Vasoactive Intestinal Peptide (VIP)
Also known as: VIP, Vasoactive Intestinal Polypeptide, Vasoactive Intestinal Peptide
Neuropeptide / Neuroendocrine peptide (secretin/glucagon family)
What it is
VIP is a natural peptide that regulates blood vessel dilation, immune function, and airway relaxation; researchers are studying it for asthma, allergic diseases, circadian rhythm disorders, and autoimmune conditions. It works by binding receptors in both the nervous and immune systems to reduce inflammation and relax smooth muscle. No FDA-approved therapeutic use in this form.
The scientific side
VIP is a 28-amino acid neuropeptide member of the secretin/glucagon family, originally isolated from porcine duodenum and later found throughout the central and peripheral nervous systems and in endocrine cells. VIP mediates its biological effects by binding to specific receptors — principally VPAC1 and VPAC2 (also designated VIP-1 and VIP-2 receptors), as well as PAC1 and CRTH2 — which are expressed on a wide variety of cell types including immune cells (eosinophils, mast cells, neutrophils, lymphocytes), smooth muscle, cardiac tissue, and neurons. Receptor binding activates adenylyl cyclase, increasing intracellular cAMP, which in turn drives downstream signaling cascades. VIP also modulates nitric oxide and cyclic GMP signaling in vascular tissues. Its actions include vasodilation, smooth muscle relaxation, anti-inflammatory and immunomodulatory effects, regulation of gastric motility, hormonal secretion, neurotrophic and neuroprotective functions, and modulation of circadian rhythms in the suprachiasmatic nucleus (SCN).
Class: Neuropeptide / Neuroendocrine peptide (secretin/glucagon family)
Administration & storage
- Administration
- Intrathecal injection (animal studiesrats) (PMID: 12860207)Intraperitoneal injection (i.p.) (animal studiesmice) (PMID: 25086267)Intracoronary or intravenous administration (human and animal cardiovascular studies) (PMID: 11121793)Intravenous infusion for 20 minutes (human cluster headache provocation study) (PMID: 37143998)Intravesical infusion of saline (cystometryVIP knockout mice) (PMID: 18561033)Intravenous injection of MNU 50 mg/kg to induce breast cancer model (ratnot VIP administration) (PMID: 11245339)
- Storage
- No storage conditions for VIP are described in the reviewed abstracts.
- Cautions
- VIP is reported to be rapidly degraded in vivo; metabolic instability is a recognized limitation of native VIP, and VIP-based drugs are described as not yet in clinical use partly because of poor metabolic stability and poor penetration to desired sites of action.,Tyrosine residues (Tyr10 and Tyr22) of VIP can be nitrated under inflammatory/oxidative conditions (heme or Cu2+ with H2O2 and NO2-), which dramatically decreases alpha-helix content and reduces cAMP secretion, indicating that the peptide may lose biological activity in inflammatory environments.,Intrathecal VIP produced early antinociception followed by hyperalgesia in a concentration-dependent manner in rats; the dual and opposing effects of VIP on nociception indicate complex, dose-dependent pharmacology.,Long-term i.p. administration of native VIP (not VIP-TAT) aggravated scopolamine-induced amnesia in mice, suggesting VIP may exert opposite effects in brain versus peripheral compartments depending on delivery method.,No human safety, tolerability, or pharmacokinetic data for exogenously administered VIP are described in the reviewed abstracts. Use of any research-grade peptide outside of a supervised clinical setting carries inherent risks. Sterile technique is essential for any injectable preparation.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Cardiovascular effects (vasodilation, coronary blood flow, cardiac contractility, heart rate modulation) Mixed
- VIP is 50–100 times more potent than acetylcholine as a vasodilator on a molar basis. In humans and research animals, intracoronary or intravenous VIP increases epicardial coronary artery cross-sectional area, decreases coronary vascular resistance, and increases coronary artery blood flow. VIP also exerts positive ino PMID 11121793 Henning RJ, Sawmiller DR. Cardiovascular research (2001)
- Immunomodulation and allergic disease (asthma, allergic rhinitis, atopic dermatitis) Mixed
- VIP mediates immunological functions through VPAC1, VPAC2, CRTH2, and PAC1 receptors on immune cells. VIP action varies by target organ, specific receptors, involved immune cells, and organ microenvironment. Review identifies VIP as a potential therapeutic target in asthma, allergic rhinitis, and atopic dermatitis. PMID 28964637 Verma AK et al. Cytokine & growth factor reviews (2017)
- In asthmatic mice, VIP and a VIP-MapA-α-alumina drug delivery system reduced eosinophil percentage, IgE, IL-4, IL-5, IL-13, ROS levels, GATA3 and MUC5AC gene expression, goblet cell hyperplasia, mucus hyper-production, and perivascular/peribronchial inflammation. VIP-MapA had a stronger effect than VIP alone. PMID 37143998 Jia W, Yang D. Postepy dermatologii i alergologii (2023)
- VIP modulates maturation of immune effector cells, T cell recognition, antibody production, and homing capabilities. Effects are tissue-specific and dependent on microenvironment, presence of other signal molecules, and activational state of target cells. PMID 8790778 Bellinger DL et al. Advances in neuroimmunology (1996)
- Circadian rhythm regulation (suprachiasmatic nucleus pacemaker function) Animal studies only
- Approximately 10% of SCN neurons express VIP. High-frequency (but not low-frequency) VIP neuron stimulation shifted gene expression rhythms in vitro through VIP signaling, and high-frequency VIP neuron activation in vivo rapidly entrained circadian locomotor rhythms in mice. PMID 30017392 Mazuski C et al. Neuron (2018)
- Ablation of VIP SCN neurons in adult mice caused shortened circadian period, more variable activity onsets, and severely dampened corticosterone rhythms. Deletion of neonatal SCN VIP neurons dramatically reduced circadian gene expression, mimicking global VIP or VIPR2 deletion. PMID 32536240 Mazuski C, Chen SP, Herzog ED. Journal of biological rhythms (2020)
- Reduced VIP expression in VIP-IRES-Cre mice altered circadian period and network organization. Arginine vasopressin signaling was found to help sustain SCN function when VIP is reduced. PMID 32460660 Joye DAM et al. Journal of biological rhythms (2020)
- Homozygous Vip-tTA knock-in mice (VIP absent) showed impaired circadian behavioral rhythms with attenuated rhythmicity and shortened circadian period, similar to VIP knockout mice. PMID 35592033 Peng Y et al. Frontiers in physiology (2022)
- Cancer cell proliferation and tumor imaging (breast, lung, pancreatic, glioblastoma) Mixed
- VIP causes increased proliferation of human breast and lung cancer cells in vitro, binds with high affinity to cancer cells, elevates cAMP, and increases gene expression of c-fos, c-jun, c-myc, and VEGF. VIPhybrid (synthetic VPAC1 antagonist) inhibited basal growth of lung cancer cells in vitro and tumors in vivo and p PMID 12576099 Moody TW et al. Peptides (2003)
- VIP-1 receptor mRNA detected in 28 human ductal pancreatic adenocarcinomas; 100 pM VIP stimulated significant growth of VIP-1 receptor-bearing Capan-2 cells in vitro both in the absence and presence of serum. PMID 9108448 Jiang S et al. Cancer research (1997)
- VIP receptors (predominantly VPAC1 subtype) are overexpressed in MNU-induced rat breast cancer tissue compared to normal breast tissue; results suggest the MNU-rat model can be used to study VIP-receptor-mediated breast cancer targeting. PMID 11245339 Dagar S et al. Breast cancer research and treatment (2001)
- VIP and PACAP-38 significantly reduced glioblastoma cell invasion in rat brain parenchyma ex vivo and migration in vitro via PKA-dependent blockade of PI3K/Akt and SHH/GLI1 pathways. VIP receptor system antagonist increased invasion. PMID 30669581 Bensalma S et al. Cancers (2019)
- Airway smooth muscle relaxation and bronchodilation Human observational
- VIP and peptide histidine methionine (PHM) caused dose-dependent relaxation of human bronchi approximately 50-fold more potent than isoproterenol. VIP mimicked the time course of nonadrenergic inhibitory nerve stimulation. Bronchioles did not relax to VIP or PHM. PMID 3781947 Palmer JB et al. Journal of applied physiology (1986)
- VIP antagonists significantly enhanced electrically evoked contractions in human bronchus by a prejunctional mechanism, suggesting endogenous VIP suppresses acetylcholine release from vagal nerve terminals in the human airway. PMID 8201830 Aizawa H et al. Lung (1994)
- Urinary bladder function and inflammation Animal studies only
- VIP(-/-) mice showed increased bladder mass, altered voiding patterns, increased urea permeability, and exaggerated bladder hyperreflexia and somatic sensitivity following cyclophosphamide-induced bladder inflammation, suggesting VIP is an endogenous anti-inflammatory agent in the urinary bladder. PMID 18561033 Studeny S et al. Journal of molecular neuroscience (2008)
- Peripheral nerve regeneration Animal studies only
- VIP (and PACAP) promoted myelin gene expression in cultured rat Schwann cells and inhibited pro-inflammatory cytokine release. VIP and PACAP receptors (VPAC1, VPAC2, PAC1) were upregulated in the distal nerve following peripheral nerve injury and highly expressed in Schwann cells and macrophages, implicating VIP in rem PMID 31920495 Woodley PK et al. Frontiers in neuroscience (2019)
- Hippocampal synaptic plasticity and cognitive function Animal studies only
- Review finds VIP regulates GABAergic transmission and pyramidal cell activity in the hippocampus through VIP-containing basket cells and interneuron-selective interneurons, controls synaptic plasticity phenomena (LTP, LTD), and is implicated in hippocampal-dependent cognition. VPAC1 and VPAC2 receptors are discussed as PMID 32595454 Cunha-Reis D, Caulino-Rocha A. Frontiers in cellular neuroscience (2020)
- VIP-TAT (VIP fused with cell-penetrating TAT peptide) inhibited scopolamine-induced amnesia in mice after both short-term and long-term i.p. injection, inhibiting oxidative damage, apoptosis, and cholinergic system activity reduction. Long-term i.p. VIP alone aggravated scopolamine-induced amnesia. VIP-TAT had higher a PMID 25086267 Yu R et al. Peptides (2014)
- Ovarian health and prevention of premature ovarian aging Animal studies only
- Young VIP knockout mice showed aberrant ovarian morphology with increased atretic follicles, decreased ovarian reserve, reduced vascularization, increased collagen deposition, elevated ROS and IL-1β, and predominance of foamy macrophages indicating premature aging. VIP KO macrophages showed increased lipid droplet accu PMID 39894337 Castagnola L et al. Molecular and cellular endocrinology (2025)
- Nociception/pain modulation Animal studies only
- Intrathecal injection of aqueous (random coil) VIP evoked a significant bimodal, concentration-dependent response — early potent antinociception followed by hyperalgesia — during exposure to low and high rates of noxious radiant skin heating in anesthetized rats. Alpha-helix VIP (in sterically stabilized phospholipid m PMID 12860207 Yeomans DC et al. Peptides (2003)
- Skin conditions (eczema, psoriasis) — elevated VIP as biomarker Human observational
- VIP concentrations were elevated in skin biopsies from patients with eczema and psoriasis but not in axillary hyperhidrosis. Substance P and somatostatin levels did not differ from controls. VIP may increase local blood flow in eczema and psoriasis. PMID 1712221 Anand P et al. British journal of dermatology (1991)
- Fetal growth and placental glucose transport Animal studies only
- VIP-deficient placentas in mice showed paradoxically higher glucose uptake and higher GLUT1 and mTOR expression, yet fetal weight was reduced. VIP-deficient pregnancies in a normal maternal background modeled fetal growth restriction; maternal VIP deficiency increased placental and transplacental glucose transport rega PMID 34186168 Merech F et al. BBA Molecular Basis of Disease (2021)
- Cluster headache — VIP as biomarker/provocateur Human observational
- VIP infusion provoked cluster headache attacks in episodic and chronic cluster headache patients. Plasma VIP levels during PACAP infusion increased significantly in episodic cluster headache patients in active phase and remission but not in chronic cluster headache. Cluster headache attacks induced by PACAP38 or VIP in PMID 37143998 Deligianni C et al. Frontiers in neurology (2023)
- CMV infection and myeloid-derived suppressor cell immunomodulation Animal studies only
- VIP-/- mice showed reduced circulating monocytic MDSCs versus wild-type mice after MCMV infection. VIP-/- MDSCs secreted less NO upon LPS/interferon stimulation and relatively lost the ability to suppress T cell activation compared to WT MDSCs. VIP activation enhanced the immunosuppressive effect of MDSCs on CMV-induce PMID 29137229 Forghani P et al. Oncotarget (2017)
Safety signals
- VIP rapidly degraded in vivo; poor metabolic stability identified as a major obstacle preventing clinical use of VIP-based drugs PMID 18172612
- Intrathecal VIP produced concentration-dependent hyperalgesia (following initial antinociception) in rats, indicating potential for paradoxical pain-sensitizing effects PMID 12860207
- Tyrosine nitration (Tyr10 and Tyr22) of VIP under inflammatory/oxidative conditions (heme or Cu2+) significantly decreased cAMP secretion in SHSY-5Y cells, suggesting loss of anti-inflammatory efficacy in disease states PMID 37481062
- Long-term systemic (i.p.) VIP administration in mice aggravated scopolamine-induced amnesia, opposite to the neuroprotective effect of VIP-TAT, suggesting route- and formulation-dependent adverse cognitive effects PMID 25086267
- VIP stimulates proliferation of human breast and lung cancer cells in vitro and increases VEGF gene expression; VPAC1 receptors overexpressed in multiple cancer types may confer pro-tumorigenic signaling by endogenous or exogenous VIP PMID 12576099
- VIP knockout mice show premature ovarian aging with increased atretic follicles, fibrosis, and elevated ROS and IL-1β, illustrating the physiological importance of endogenous VIP for ovarian homeostasis; perturbation of VIP signaling may have reproductive consequences PMID 39894337
Contraindications
- No explicit contraindications for exogenous VIP administration in humans are stated in the reviewed abstracts. Use in individuals with active cancer is a theoretical concern given VIP's documented ability to stimulate proliferation of breast, lung, and pancreatic cancer cells in vitro and upregulate VEGF. PMID 12576099
- VIP deficiency (knockout) in mice resulted in exaggerated bladder hyperreflexia and inflammation; however, no contraindications to exogenous VIP in patients with bladder conditions are explicitly stated in the reviewed abstracts. PMID 18561033
Protocol
50 mcg intranasal, once daily. Cycle: 4-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro (cell culture) | 100 pM (stimulating); 1 nM (non-stimulating); 1 µM (used for cAMP studies) | Not specified (in vitro experiments) | in_vitro | Research PMID 9108448 |
| Endogenous measurement (saliva) | Endogenous salivary VIP measured; no exogenous dose administered | Single stress exposure | human | Research PMID 23994551 |
| Intrathecal injection | Multiple concentrations tested (concentration-dependent effects described; specific concentrations not enumerated in abstract) | Single session | animal | Research PMID 12860207 |
| Intracoronary or intravenous (human and animal studies cited) | 10(-8)–10(-5) mol (augments isometric force and atrial/ventricular contractility) | Not specified | human | Research PMID 11121793 |
| In vitro (tissue sections) | 40 nM fluorescein-labeled VIP (Fluo-VIP); 1000-fold excess unlabeled VIP for displacement | Single incubation | in_vitro | Research PMID 11245339 |
| Intravenous infusion | VIP infusion for 20 minutes (specific dose/rate not stated in abstract) | 20-minute infusion | human | Research PMID 37143998 |
| In vitro (organ bath) | 10(-10) to 10(-7) M VIP tested on human airway tissue in vitro | Single in vitro experiment | in_vitro | Research PMID 3781947 |
| In vitro (organ bath, human bronchus) | 10(-10) to 10(-7) M (VIP, no effect on EFS contractions); 10(-8) M (VIP antagonists, significant enhancement of contractions) | Single in vitro experiment | in_vitro | Research PMID 8201830 |
| In vitro (cell culture, IGR39 human melanoma cells) | 0.78 nM (half-maximal cAMP); 10 nM (maximal cAMP ~100x basal); 1 µM (receptor downregulation) | Single in vitro experiment | in_vitro | Research PMID 2538331 |
| Optogenetic (in vivo and in vitro, mice) | High-frequency vs. low-frequency optogenetic stimulation of VIP neurons (specific Hz ranges not quantified in abstract for VIP release threshold) | In vitro and in vivo experiments in mice | animal | Research PMID 30017392 |
| intranasal | 50 mcg | once daily · 4-12 weeks | biohackers and CIRS/mold illness patients seeking neurological and inflammatory symptom relief | [Community] |
| intranasal | 50 mcg | twice daily (BID) · 4-12 weeks | CIRS patients or biohackers with more significant inflammatory burden | [Community] |
| intranasal | 100 mcg | twice daily (BID) · 4-12 weeks | CIRS patients with persistent or severe symptoms, often under practitioner guidance | [Community] |
| intranasal | 25 mcg | once daily · 2-8 weeks | biohackers new to VIP, sensitive individuals, or those titrating up | [Community] |
| subcutaneous injection | 50 mcg | once daily · 4-8 weeks | biohackers preferring injectable peptides, or those who find intranasal administration inconsistent | [Community] |
| intranasal | 50 mcg | once daily (morning only) · ongoing / open-ended | long-term biohackers using VIP as part of a longevity or nootropic stack | [Community] |
All studies (27)
- PMID 1712221 Human observational
Skin conditions (eczema, psoriasis) — elevated VIP as biomarker - PMID 3781947 Human observational
Airway smooth muscle relaxation and bronchodilation - PMID 8201830 Human observational
Airway smooth muscle relaxation and bronchodilation - PMID 8790778 Mixed
Immunomodulation and allergic disease (asthma, allergic rhinitis, atopic dermatitis) - PMID 9108448 Mixed
Cancer cell proliferation and tumor imaging (breast, lung, pancreatic, glioblastoma) - PMID 11121793 Mixed
Cardiovascular effects (vasodilation, coronary blood flow, cardiac contractility, heart rate modulat - PMID 11245339 Mixed
Cancer cell proliferation and tumor imaging (breast, lung, pancreatic, glioblastoma) - PMID 12576099 Mixed
Cancer cell proliferation and tumor imaging (breast, lung, pancreatic, glioblastoma) - PMID 28964637 Mixed
Immunomodulation and allergic disease (asthma, allergic rhinitis, atopic dermatitis) - PMID 30669581 Mixed
Cancer cell proliferation and tumor imaging (breast, lung, pancreatic, glioblastoma) - PMID 37143998 Mixed
Immunomodulation and allergic disease (asthma, allergic rhinitis, atopic dermatitis) - PMID 2538331
0.78 nM (half-maximal cAMP); 10 nM (maximal cAMP ~100x basal); 1 µM (receptor downregulation) In vitro (cell culture, IGR39 human melanoma cells) (in_vitro) - PMID 12860207 Animal studies only
Nociception/pain modulation - PMID 18172612
VIP rapidly degraded in vivo; poor metabolic stability identified as a major obstacle preventing clinical use of VIP-based drugs - PMID 18561033 Animal studies only
Urinary bladder function and inflammation - PMID 23994551
Endogenous salivary VIP measured; no exogenous dose administered Endogenous measurement (saliva) (human) - PMID 25086267 Animal studies only
Hippocampal synaptic plasticity and cognitive function - PMID 29137229 Animal studies only
CMV infection and myeloid-derived suppressor cell immunomodulation - PMID 30017392 Animal studies only
Circadian rhythm regulation (suprachiasmatic nucleus pacemaker function) - PMID 31920495 Animal studies only
Peripheral nerve regeneration - PMID 32460660 Animal studies only
Circadian rhythm regulation (suprachiasmatic nucleus pacemaker function) - PMID 32536240 Animal studies only
Circadian rhythm regulation (suprachiasmatic nucleus pacemaker function) - PMID 32595454 Animal studies only
Hippocampal synaptic plasticity and cognitive function - PMID 34186168 Animal studies only
Fetal growth and placental glucose transport - PMID 35592033 Animal studies only
Circadian rhythm regulation (suprachiasmatic nucleus pacemaker function) - PMID 37481062
Tyrosine nitration (Tyr10 and Tyr22) of VIP under inflammatory/oxidative conditions (heme or Cu2+) significantly decreased cAMP secretion in SHSY-5Y cells, sugg - PMID 39894337 Animal studies only
Ovarian health and prevention of premature ovarian aging